At the time of writing, Biomarin Pharmaceutical Inc. [BMRN] stock is trading at $90.21, up 1.38%. An important factor to consider is whether the stock is rising or falling in short-term value. The BMRN shares have gain 3.95% over the last week, with a monthly amount glided 4.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 10, April 2024, BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET. In a post published today on Yahoo Finance, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.
From an analyst’s perspective:
Biomarin Pharmaceutical Inc. [NASDAQ: BMRN] stock has seen the most recent analyst activity on November 15, 2023, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $100. Previously, Bernstein upgraded its rating to Mkt Perform on October 23, 2023, and kept the price target unchanged to $82. On September 28, 2023, Raymond James initiated with a Mkt Perform rating. UBS started tracking the stock assigning a Buy rating and suggested a price target of $120 on September 18, 2023. Scotiabank initiated its recommendation with a Sector Perform and recommended $95 as its price target on July 27, 2023. BMO Capital Markets upgraded its rating to Outperform for this stock on July 05, 2023, but kept the price target unchanged to $102.
For the past year, the stock price of Biomarin Pharmaceutical Inc. fluctuated between $76.02 and $100.38. Currently, Wall Street analysts expect the stock to reach $117.1 within the next 12 months. Biomarin Pharmaceutical Inc. [NASDAQ: BMRN] shares were valued at $90.21 at the most recent close of the market. An investor can expect a potential return of 29.81% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
According to Biomarin Pharmaceutical Inc. [NASDAQ:BMRN], the company’s sales were 2.42B for trailing twelve months, which represents an 25.23% jump. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.03 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.53 points at the first support level, and at 86.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.15, and for the 2nd resistance point, it is at 92.09.
Biomarin Pharmaceutical Inc. [BMRN] reported earnings per share of $0.11 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.23/share, meaning a difference of -$0.12 and a surprise factor of -52.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.21 per share as compared to estimates of $0.23 per share, a difference of -$0.02 representing a surprise of -8.70%.
Ratios To Look Out For
It is important to note that Biomarin Pharmaceutical Inc. [NASDAQ:BMRN] has a current ratio of 2.51. On the other hand, the Quick Ratio is 1.57, and the Cash Ratio is 6415.56. Considering the valuation of this stock, the price to sales ratio is 7.04, the price to book ratio is 3.44 and price to earnings (TTM) ratio is 103.55.
Transactions by insiders
Recent insider trading involved Davis George Eric, EVP, Chief Legal Officer, that happened on Mar 28 ’24 when 24602.0 shares were sold. Director, BIENAIME JEAN JACQUES completed a deal on Mar 06 ’24 to sell 1000.0 shares. Meanwhile, President, Worldwide R&D FUCHS HENRY J sold 35341.0 shares on Mar 05 ’24.
